Overexpression of STX11 alleviates pulmonary fibrosis by inhibiting fibroblast activation via the PI3K/AKT/mTOR pathway

Guichuan Huang,Xiangsheng Yang,Qingyang Yu,Qun Luo,Chunrong Ju,Bangyan Zhang,Yijing Chen,Zihan Liang,Shu Xia,Xiaohua Wang,Dong Xiang,Nanshan Zhong,Xiao Xiao Tang

DOI: https://doi.org/10.1038/s41392-024-02011-y

IF: 39.3

2024-11-12

Signal Transduction and Targeted Therapy

Abstract:Fibroblast activation plays an important role in the occurrence and development of idiopathic pulmonary fibrosis (IPF), which is a progressive, incurable, and fibrotic lung disease. However, the underlying mechanism of fibroblast activation in IPF remains elusive. Here, we showed that the expression levels of STX11 and SNAP25 were downregulated in the lung tissues from patients with IPF and mice with bleomycin (BLM)-induced lung fibrosis as well as in the activated fibroblasts. Upregulation of STX11 or SNAP25 suppressed TGF-β1-induced activation of human lung fibroblasts (HLFs) via promoting autophagy. However, they failed to suppress fibroblast actviation when autophagy was blocked with the use of chloroquine (CQ). In addition, STX11 or SNAP25 could inhibit TGF-β1-induced fibroblast proliferation and migration. In vivo, overexpression of STX11 exerted its protective role in the mice with BLM-induced lung fibrosis. STX11 and SNAP25 mutually promoted expression of each other. Co-IP assay indicated that STX11 has an interaction with SNAP25. Mechanistically, STX11-SNAP25 interaction activated fibroblast autophagy and further inhibited fibroblast activation via blocking the PI3K/AKT/mTOR pathway. Overall, the results suggested that STX11-SNAP25 interaction significantly inhibited lung fibrosis by promoting fibroblast autophagy and suppressing fibroblast activation via blocking the PI3K/ATK/mTOR signaling pathway. Therefore, STX11 serves as a promising therapeutic target in IPF.

biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The paper attempts to address the pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) and its potential therapeutic targets. Specifically, the authors focus on the role of STX11 in IPF and its interaction with SNAP25. The main issues of the paper are as follows:

1. **Changes in STX11 expression in IPF**: The study found that STX11 expression is decreased in IPF patients and in a bleomycin (BLM)-induced mouse model of pulmonary fibrosis.

2. **Effect of STX11 on fibroblast activation**: Overexpression of STX11 can inhibit the activation of human lung fibroblasts (HLFs) induced by transforming growth factor β1 (TGF-β1) and promote autophagy.

3. **Interaction between STX11 and SNAP25**: There is a mutually promoting relationship between STX11 and SNAP25 expression, and they inhibit fibroblast activation by forming a complex.

4. **Mechanism of action of the STX11-SNAP25 complex**: The STX11-SNAP25 complex inhibits fibroblast activation and autophagy by blocking the PI3K/AKT/mTOR signaling pathway.

5. **Role of STX11 in mouse models**: Overexpression of STX11 can alleviate BLM-induced pulmonary fibrosis in mice, suggesting that STX11 may be a potential therapeutic target.

In summary, this paper aims to reveal the role of STX11 in IPF and its potential therapeutic value, particularly by regulating autophagy and inhibiting the PI3K/AKT/mTOR signaling pathway to suppress fibroblast activation.